Virtual Library
Start Your Search
I. Pousa
Author of
-
+
P3.02a - Poster Session with Presenters Present (ID 470)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02a-028 - Anaplastic Lymphoma Kinase Fusion Oncogene Positive Non-Small Cell Lung Cancer - The Experience of an Institution (ID 5783)
14:30 - 14:30 | Author(s): I. Pousa
- Abstract
Background:
Approximately 3–7% of lung tumors harbor Anaplastic Lymphoma Kinase (ALK) fusions. The aim of the current study was to characterize the population of patients with ALK positive non small cell lung cancer (NSCLC) treated at our Institution.
Methods:
Retrospective analysis of 26 ALK positive NSCLC, diagnosed between December/2008 and February/2016. Eligible patients had lung adenocarcinoma harboring ALK translocation according to fluorescent in situ hybridization. Best response was assessed using RECIST (version 1.1).
Results:
Twenty six patient cases are reported, diagnosed between 01/12/2008 and 29/02/2016. Median age was 56 years, 60.7% of patients were women, and 71.4% were never-smokers. Twenty-four (92.3%) were adenocarcinomas. All patients were EGFR negative. Twenty (76.9%) were stage IV. Fifteen patients (57.7%) were treated in first line with palliative chemotherapy (CT), thirteen of them with platinum/pemetrexed. Twelve patients (46.1%) were treated with crizotinib, two in first line, nine in second line and one in third line; one patient was treated with ceritinib in fourth line. As major adverse events there were eight cases (30.7%) of venous thromboembolism, including five (19.2%) pulmonary embolisms. ALK directed therapy, namely crizotinib, was safe and well-tolerated. Most of the patients (91.7%) were treated with the standard dose of 250mg twice per day. One patient needed dose reduction due to hepatotoxicity (G3, CTCAE.V4). The most frequent treatment-related adverse events were emesis (G1) vision disorders (G1), and increased AST/ALT (G3). Three patients treated with CT had grade 3 toxicity (pneumonia with respiratory failure, anemia, peripheral neuropathy). Median follow-up of study population was 13.5 months. In patients treated with crizotinib objective response rate (ORR = complete response + partial response) was 50% and clinical benefit (CB = complete response + partial response + stable disease) was 75%. In patients treated with CT ORR was 6.7% and CB was 73%. Seven (26.9%) patients died during the study period. Median overall survival has not been reached.
Conclusion:
ALK directed therapy provided increased benefit and lower toxicity compared to CT. During the study period, there were several treatment guidelines updates impacting the patient’s management. Presented results are consistent with the published literature.
